Inflammatory Bowel Disease

>

Latest News

Guselkumab (Tremfya) Wins Approval for Crohn Disease, Fourth Indication for Immune-Mediated Diseases / image credit ©MichaelVi/stock.adobe.com
Guselkumab (Tremfya) Wins Approval for Crohn Disease, Fourth Indication for Immune-Mediated Diseases

March 21st 2025

The IL-23 inhibitor is the only drug in the class available with both subcutaneous and intravenous administration options for treatment induction, according to J&J.

FDA Approves Mirikizumab for Crohn Disease: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Approves Mirikizumab for Crohn Disease: Daily Dose

January 27th 2025

Landmark International Trial Seeks to Intercept and Prevent Crohn Disease Using Biomarkers / image credit ©rookielion/stock.adobe.com
Landmark International Trial Seeks to Intercept and Prevent Crohn Disease Using Biomarkers

January 22nd 2025

FDA Approves Lilly’s Mirikizumab-mrkz for Crohn’s Disease ©MichaelVi/stock.adobe.com
FDA Approves Lilly’s Mirikizumab-mrkz for Crohn’s Disease

January 16th 2025

January Issue of Patient Care Online Digital Edition is Now Live / Image credit: ©MJH Life Sciences
January Issue of Patient Care Online Digital Edition is Now Live

December 16th 2024

Video Series
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.